The commercial intelligence platform that turns healthcare data into the next surgeon a medical device rep should call.
In most industries, the sales rep already knows who to call. In medical devices, that has never been obvious. A new surgical implant or diagnostic tool succeeds or fails on whether the right surgeon, at the right hospital, doing the right volume of the right procedure, hears about it - and trusts the person explaining it. For years, the reps chasing those relationships worked half-blind, logging notes into a CRM that told them nothing about where the actual opportunity sat.
AcuityMD, founded in Boston in 2019, was built to fix exactly that. It is a commercial intelligence platform made specifically for the medical device (MedTech) industry. It ingests large volumes of healthcare claims and procedure data - more than 325 million patient records - and turns them into something a salesperson can act on: this physician, this care site, this market, this quarter.
The pitch is deceptively plain. As co-founder and CEO Michael Monovoukas has put it, reps "spend their days in their office logging notes into a CRM instead of educating surgeons about new technologies." AcuityMD's answer is software that hands them the answer instead of asking them to record the question.
At its core, AcuityMD is a data-and-workflow layer. The data side aggregates medical claims, procedure and diagnosis codes, physician referral patterns, and product-usage signals. The workflow side translates all of it into recommendations that fit how device companies actually operate - by territory, by market, by account, and by opportunity.
The users are medical device manufacturers, from pre-commercial startups launching a single product to global enterprises with thousands of reps. Named customers span Olympus, Teleflex, Becton Dickinson, Enovis, Merit Medical, Route 92 Medical, Intellijoint Surgical, Pristine Surgical, and Spark Biomedical. The company says it serves 16 of the top 20 MedTech firms - an unusually deep penetration of an enterprise category for a startup its age.
Device commercial teams historically stitched together claims databases, spreadsheets, and generic CRMs to answer basic questions: Where are the high-volume procedures? Which surgeons already use a competitor? How big is this market, really? AcuityMD collapses that into one platform, so reps spend less time assembling data and more time in front of physicians. The company markets a blunt outcome from its AI features: users are "3x more likely to hit quota."
"They spend their days in their office logging notes into a CRM instead of educating surgeons about new technologies."
Michael Monovoukas, Co-founder & CEOSurfaces high-value providers and care sites using procedure volumes and historical product usage - the "who to call next" engine.
Defines, sizes, and segments target markets from procedure and diagnosis codes plus geographic filters.
Balances sales coverage and resource allocation with region-specific data for fair, data-driven territory design.
Automates sales-cycle management, opportunity tracking, and forecasting - replacing manual CRM logging.
Traces patient pathways and physician referral networks to reveal upstream referrers and adoption openings.
An agentic AI layer that recommends next steps, drafts outreach, and answers commercial questions across the platform.
AcuityMD sells annual B2B SaaS subscriptions to device manufacturers - typically a base platform fee plus per-seat licenses, with revenue expanding as customers adopt more modules and seats. Reported ranges put base tiers in the tens of thousands of dollars, with roughly $2K per user per year on top.
That model has attracted a marquee investor roster. The company raised a $7M seed in 2021, a $31M Series A in 2022, a $45M Series B in 2024, and an $80M Series C in April 2026 led by StepStone Group - pushing total funding past $160M and its valuation to roughly $955M, near unicorn territory.
Backers include Benchmark, Redpoint Ventures, ICONIQ, StepStone Group, and Atreides Management.
The obvious comparisons are healthcare-data giants like Definitive Healthcare and IQVIA. But those platforms serve broad audiences - pharma, providers, payers - and often sit outside the rep's daily workflow. AcuityMD's wager is specificity: it focuses only on the medical device commercial motion, and it lives where reps work.
Its credibility starts with its founders. Monovoukas advised device and biopharma clients on commercial strategy at Bain & Company; co-founder Lee Smith came from marketing at Medtronic; CTO Robert Coe built sales-engineering systems at Yext. They sell software back to the industry they came from - a domain fit that is hard for a horizontal competitor to replicate.
Pharma has had sophisticated commercial-intelligence tooling for decades. Medical devices - where the right surgeon matters more than the right zip code - were largely skipped. AcuityMD positioned itself as the intelligence layer for that overlooked middle, and the enterprise adoption suggests the gap was real. The company's stated next chapter is agentic AI on top of a strengthened data model, funded directly by the Series C.
Michael Monovoukas, Robert Coe, and Lee Smith launch AcuityMD to modernize medical device commercialization.
Benchmark and Redpoint back the first modules built on claims data.
Redpoint leads as ARR grows triple digits and customer count climbs.
ICONIQ Growth backs expansion to more medical technology manufacturers.
An agentic AI insights layer rolls out across the commercial modules.
StepStone Group leads a round to accelerate AI and data investment, valuing AcuityMD at ~$955M.
It provides a commercial intelligence platform for medical device companies, turning healthcare claims and procedure data into targeting, market sizing, territory planning, and pipeline tools for sales and marketing teams.
Medical device and MedTech manufacturers - from pre-commercial startups to global enterprises - use it for their commercial teams. The company reports serving 16 of the top 20 MedTech firms.
More than $160M total across seed, Series A ($31M), Series B ($45M), and an $80M Series C in April 2026, which valued the company at roughly $955M.
It was founded in 2019 by Michael Monovoukas (CEO), Robert Coe (CTO), and Lee Smith, who came from consulting, sales engineering, and MedTech marketing backgrounds.
AcuityMD focuses specifically on the medical device commercial workflow - who to call, which markets to enter, how to manage device sales cycles - rather than serving pharma or general healthcare data needs, and it lives in reps' daily workflow.
Sources: AcuityMD, MobiHealthNews, MedTech Dive, MassDevice, BusinessWire, Built In Boston, HLTH, Contrary Research. Figures are company-reported or press-reported and approximate.